Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Type 2 diabetes (T2D) is a public health threat. Prediabetes represents a window of opportunity for intervention to prevent T2D. Men with T2D and prediabetes often have low testosterone. Since testosterone improves glycemic control in T2D, we investigated whether testosterone therapy (TTh) in men with hypogonadism and prediabetes prevents progression to T2D. RESEARCH DESIGN AND METHODS: Three hundred and sixteen men with prediabetes (defined as HbA1c 5.7–6.4%) and total testosterone levels ≤12.1 nmol/L combined with symptoms of hypogonadism were analyzed. Two hundred and twenty-nine men received parenteral testosterone undecanoate (T-group), and 87 men with hypogonadism served as untreated control subjects. Metabolic and anthropometric parameters were measured twice yearly for 8 years. RESULTS: HbA1c decreased by 0.39 ± 0.03% (P < 0.0001) in the T-group and increased by 0.63 ± 0.1% (P < 0.0001) in the untreated group. In the T-group, 90% achieved normal glucose regulation (HbA1c <5.7%). In the untreated group, 40.2% progressed to T2D (HbA1c >6.5%). TTh was also associated with significant improvements in fasting glucose, triglyceride:HDL ratio, triglyceride-glucose index, lipid accumulation product, total cholesterol, LDL, HDL, non-HDL, triglycerides, and Aging Males’ Symptoms (AMS) scale. Significant deterioration in all these parameters was seen in the untreated group. Mortality was 7.4% in the T-group and 16.1% in the untreated group (P < 0.05). The incidence of nonfatal myocardial infarction was 0.4% in the T-group and 5.7% in the untreated group (P < 0.005). CONCLUSIONS: Long-term TTh completely prevents prediabetes progression to T2D in men with hypogonadism and improves glycemia, lipids, and AMS score. TTh holds tremendous potential for the large and growing population of men with prediabetes and hypogonadism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There appears to be a higher likelihood for undiagnosed hyperglycemia in those seeking fertility.1557”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1557]
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Guerrero-Romero, F., Simental-Mendía, L. E., González-Ortiz, M., Martínez-Abundis, E., Ramos-Zavala, M. G., Hernández-González, S. O., Jacques-Camarena, O., & Rodríguez-Morán, M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0288 · Cited by 2,247
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 2×
“above which further weight loss may not result in additional preventive benefits (11).”
BackgroundSelf-citationSex differences in metabolic regulation and diabetes susceptibility
Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020) · Diabetologia · doi:10.1007/s00125-019-05040-3 · Cited by 923
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865 · cited 2×
“Clinical trials assessing efficacy of lifestyle interventions as well as pharmacotherapy for obesity are characterized by high attrition rates (22).”
BackgroundEight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
The Look AHEAD Research Group (2014) · Obesity · doi:10.1002/oby.20662 · Cited by 842
The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study
Bommer, C., Heesemann, E., Sagalova, V., Manne-Goehler, J., Atun, R., Bärnighausen, T., & Vollmer, S. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30097-9 · Cited by 816 · cited 1×
“In 2017, therewere 451million people (ages 18–99 years) with diabetes worldwide, and 5million deaths were attributable to diabetes (39).”
BackgroundKapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 1×
“is likely improvement in insulin sensitivity (29,30).”
Srikanthan, P., & Karlamangla, A. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0435 · Cited by 785
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Research works printed but not linked: 1
- Saad, 2017, Most hypogonadal men with type 2 diabetes mellitus (T2DM) achieve HbA1c targets when treated with testosterone undecanoate injections (TU) for up to 12 years, Diabetes, 66, A305
Cited by
Sex and gender: modifiers of health, disease, and medicine
Mauvais-Jarvis, F., Bairey Merz, N., Barnes, P. J., Brinton, R. D., Carrero, J.-J., DeMeo, D. L., De Vries, G. J., Epperson, C. N., Govindan, R., Klein, S. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31561-0 · Cited by 2,001
Sex differences in metabolic regulation and diabetes susceptibility
Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020) · Diabetologia · doi:10.1007/s00125-019-05040-3 · Cited by 923
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationCorona, G., Goulis, D. G., Huhtaniemi, I., Zitzmann, M., Toppari, J., Forti, G., Vanderschueren, D., & Wu, F. C. (2020) · Andrology · doi:10.1111/andr.12770 · Cited by 431
Wittert, G., Bracken, K., Robledo, K. P., Grossmann, M., Yeap, B. B., Handelsman, D. J., Stuckey, B., Conway, A., Inder, W., McLachlan, R., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30367-3 · Cited by 362
Aktas, G., Kocak, M. Z., Bilgin, S., Atak, B. M., Duman, T. T., & Kurtkulagi, O. (2020) · The Aging Male · doi:10.1080/13685538.2019.1678126 · Cited by 212
Gannon, O. J., Robison, L. S., Salinero, A. E., Abi-Ghanem, C., Mansour, F. M., Kelly, R. D., Tyagi, A., Brawley, R. R., Ogg, J. D., & Zuloaga, K. L. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02466-2 · Cited by 127
Sex-based differences in insulin resistance
Gado, M., Tsaousidou, E., Bornstein, S. R., & Perakakis, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0245 · Cited by 138
Bilgin, S., Aktaş, G., Koçak, M. Z., Tel, B. M. A., Kurtkulağı, Ö., Duman, T. T., & Şavlı, H. (2019) · The Aging Male · doi:10.1080/13685538.2019.1632283 · Cited by 117
“One can assume that control of T2DM should be better in younger compared to older diabetic men, since testosterone has protective effect in progression of prediabetes to overt T2DM [22].”
BackgroundLate‐onset hypogonadism: metabolic impact
Grossmann, M., Ng Tang Fui, M., & Cheung, A. S. (2020) · Andrology · doi:10.1111/andr.12705 · Cited by 95
Haider, K. S., Haider, A., Saad, F., Doros, G., Hanefeld, M., Dhindsa, S., Dandona, P., & Traish, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14122 · Cited by 82
“We have previously shown that long-term TTh halted the progression of prediabetes to overt diabetes.(13) The primary objectives of this registry study were, firstly, to examine the effect of TTh on the course of glucose intolerance, with glycated haemoglobin (HbA1c) and insulin secretion as target variables, and, seco…”
BackgroundSelf-citationMechanisms underlying the metabolic actions of testosterone in humans: A narrative review
Dandona, P., Dhindsa, S., Ghanim, H., & Saad, F. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14206 · Cited by 95
“reported the effects of long-term (8 years) testosterone therapy in men with prediabetes and hypogonadism in an observational registry study.(41)”
BackgroundSelf-citationObesity, type 2 diabetes, and testosterone in ageing men
Wittert, G., & Grossmann, M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09746-5 · Cited by 101
Testosterone supplementation and bone parameters: a systematic review and meta-analysis study
Corona, G., Vena, W., Pizzocaro, A., Giagulli, V. A., Francomano, D., Rastrelli, G., Mazziotti, G., Aversa, A., Isidori, A. M., Pivonello, R., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01702-5 · Cited by 77
“Accordingly, normal, reduced or even increased aBMD has been described in T2DM [65–67].”
BackgroundInfluentialPizzocaro, A., Vena, W., Condorelli, R. A., Radicioni, A. F., Rastrelli, G., Pasquali, D., Selice, R., Ferlin, A., Foresta, C., Jannini, E. A., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01299-1 · Cited by 76
Bhasin, S., Lincoff, A. M., Nissen, S. E., Wannemuehler, K. A., McDonnell, M. E., Peters, A. L., Khan, N., Snabes, M. C., Li, X., Li, G., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.7862 · Cited by 65
Male hypogonadism: pathogenesis, diagnosis, and management
de Silva, N. L., Papanikolaou, N., Grossmann, M., Antonio, L., Quinton, R., Anawalt, B. D., & Jayasena, C. N. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00199-2 · Cited by 77
Xuan, X., Hamaguchi, M., Cao, Q., Okamura, T., Hashimoto, Y., Obora, A., Kojima, T., Fukui, M., Yuan, G., Guo, Z., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.02.037 · Cited by 64
Li, S., Zhao, Y., Yang, Y., Wang, X., Nie, M., Wu, X., Mao, J., & Veglio, F. (2020) · International Journal of Endocrinology · doi:10.1155/2020/4732021 · Cited by 65
“Second, because most of the patients included are obese, it is, therefore, prudent to extrapolate our conclusion to the nonobese population with T2DM and MetS.”
BackgroundInfluentialTestosterone therapy in diabetes and pre‐diabetes
Corona, G., Vena, W., Pizzocaro, A., Vignozzi, L., Sforza, A., & Maggi, M. (2022) · Andrology · doi:10.1111/andr.13367 · Cited by 60
Giagulli, V. A., Castellana, M., Carbone, M. D., Pelusi, C., Ramunni, M. I., Pergola, G. D., Guastamacchia, E., & Triggiani, V. (2020) · Andrology · doi:10.1111/andr.12754 · Cited by 54
Androgens, aging, and prostate health
Welén, K., & Damber, J. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09730-z · Cited by 63
“Testosterone replacement therapy (TRT) has been used with the purpose to improve or even reverse these symptoms [3, 4].”
BackgroundThe Role of testosterone treatment in patients with metabolic disorders
Corona, G., Rastrelli, G., Vignozzi, L., Barbonetti, A., Sforza, A., Mannucci, E., & Maggi, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1938548 · Cited by 48
Testosterone therapy and cardiovascular diseases
Cittadini, A., Isidori, A. M., & Salzano, A. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab241 · Cited by 45
Xu, W., Qadir, M. M. F., Nasteska, D., de Sa, P. M., Gorvin, C. M., Blandino-Rosano, M., Evans, C. R., Ho, T., Potapenko, E. S., Veluthakal, R., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112529 · Cited by 44
Giagulli, V. A., Castellana, M., Murro, I., Pelusi, C., Guastamacchia, E., Triggiani, V., & Pergola, G. D. (2019) · Nutrients · doi:10.3390/nu11122975 · Cited by 45
Late‐onset hypogonadism and lifestyle‐related metabolic disorders
Braga, P. C., Pereira, S., Ribeiro, J. C., Sousa, M., Monteiro, M. P., Oliveira, P. F., & Alves, M. G. (2020) · Andrology · doi:10.1111/andr.12765 · Cited by 46
Mushannen, T., Cortez, P., Stanford, F. C., & Singhal, V. (2019) · Children · doi:10.3390/children6050063 · Cited by 50
Correlates of testosterone change as men age
Kanabar, R., Mazur, A., Plum, A., & Schmied, J. (2022) · The Aging Male · doi:10.1080/13685538.2021.2023493 · Cited by 44
Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone
Caliber, M., & Saad, F. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.04.002 · Cited by 40
Self-citationCai, T., Hu, Y., Ding, B., Yan, R., Liu, B., Cai, L., Jing, T., Jiang, L., Xie, X., Wang, Y., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.813067 · Cited by 37
Kumari, K., Kumar, R., Memon, A., Kumari, B., Tehrim, M., Kumari, P., Shehryar, M., Islam, H., Islam, R., Khatri, M., et al. (2023) · Clinics and Practice · doi:10.3390/clinpract13020041 · Cited by 36
“9 Yassin (2019) [12] Observational study 316 TT < 12.”
BackgroundAntonič, K. G., Antonič, B., Žuran, I., & Pfeifer, M. (2020) · The Aging Male · doi:10.1080/13685538.2020.1793132 · Cited by 33
“Aging Males’ Symptoms (AMS) questionnaire [27].”
Yeo, S., Holl, K., Peñaherrera, N., Wissinger, U., Anstee, K., & Wyn, R. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s285434 · Cited by 39
The causes of adverse changes of testosterone levels in men
Wrzosek, M., Woźniak, J., & Włodarek, D. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1813020 · Cited by 40
Yin, L., Qi, S., & Zhu, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1267170 · Cited by 37
Approach to Obesity in the Older Population
Buch, A., Marcus, Y., Shefer, G., Zimmet, P., & Stern, N. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab359 · Cited by 31
EMAS position statement: Testosterone replacement therapy in older men
Kanakis, G., Pofi, R., Goulis, D. G., Isidori, A. M., Armeni, E., Erel, C. T., Fistonić, I., Hillard, T., Hirschberg, A. L., Męczekalski, B., et al. (2023) · Maturitas · doi:10.1016/j.maturitas.2023.107854 · Cited by 40
“Several observational studies have documented that TRT can improve body composition and metabolic profile in T2DM [55,56].”
BackgroundKumar, S., Khatri, M., Memon, R. A., Llerena-Velastegui, J., Zumbana-Podaneva, K., Benitez-Gutierrez, D., Nadeem, B., Anumolu, A. R., Azhar, M., & Zain, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102588 · Cited by 30
Kıvrak, M., Avcı, U., Uzun, H., & Ardıç, C. (2024) · Diagnostics · doi:10.3390/diagnostics14232634 · Cited by 48
“2 prevent the progression of prediabetes and induce remission of T 2 D [12].”
Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing
Rea, I. M., & Alexander, H. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101494 · Cited by 29
The impact of testosterone in men’s health
Ide, H. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej22-0604 · Cited by 38
Hypogonadism and metabolic syndrome: review and update
Berg, W. T., & Miner, M. M. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000582 · Cited by 26
Sex differences in type 2 diabetes: an opportunity for personalized medicine
Johnson, M. L., Preston, J. D., Rashid, C. S., Pearson, K. J., & Ham, J. N. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00571-2 · Cited by 35
“Indeed, T supplementation in such patients provides a staggering improvement in all-cause mortality [26].”
BackgroundRusso, G. T., Manicardi, V., Rossi, M. C., Orsi, E., & Solini, A. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.08.011 · Cited by 32
Controversies in Testosterone Therapy
Twitchell, D. K., Pastuszak, A. W., & Khera, M. (2020) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.09.004 · Cited by 29
Assyov, Y. S., Gateva, A., Karamfilova, V., Gatev, T., Nedeva, I., Velikova, T. V., & Kamenov, Z. A. (2020) · The Aging Male · doi:10.1080/13685538.2020.1770721 · Cited by 24
Wang, L., Ma, C., Wei, D., Wang, M., Xu, Q., Wang, J., Yu, S., Huo, W., Jing, T., Wang, C., et al. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122213 · Cited by 26
The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
Kırlangıç, O. F., Yilmaz‐Oral, D., Kaya‐Sezginer, E., Toktanis, G., Tezgelen, A. S., Sen, E., Khanam, A., Öztekin, Ç. V., & Gür, S. (2020) · Sexual Medicine · doi:10.1016/j.esxm.2020.02.006 · Cited by 23
“On the other hand, long-term T therapy significantly improved triglycerides, triglyceride-glucose index, lipid accumulation, total cholesterol, HDL ratio, LDL, HDL, and non-HDL.(138)”
BackgroundTestosterone, Diabetes Risk, and Diabetes Prevention in Men
Yeap, B. B., & Wittert, G. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.004 · Cited by 21
Cardiometabolic indices predict hypogonadism in male patients with type 2 diabetes
Caretta, N., Facondo, P., Mereu, S., Delbarba, A., Crepaldi, M., Vedovato, M., Avogaro, A., & Ferlin, A. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01941-0 · Cited by 21
“1 3 profile, disease control, and prognosis [8, 10, 31].”
Khera, M., Torres, L. O., Grober, E. D., Morgentaler, A., Miner, M. M., Jones, T. H., Mills, J. N., & Salonia, A. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf036 · Cited by 26
Al‐Zoubi, R. M., Yassin, A. A., Alwani, M. M., Al-Qudimat, A. R., Aboumarzouk, O. M., Zarour, A. M., & Ansari, A. A. (2021) · Arab Journal of Urology · doi:10.1080/2090598x.2021.1959260 · Cited by 19
Self-citationLeutner, M., Matzhold, C., Bellach, L., Wohlschläger‐Krenn, E., Winker, R., Nistler, S., Endler, G., Thurner, S., Klimek, P., & Kautzky‐Willer, A. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01903-1 · Cited by 21
Mo, Q., Deng, X., Zhou, Z., & Yin, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104777 · Cited by 23
Glucose Homeostasis, Diabetes Mellitus, and Gender-Affirming Treatment
Milionis, C., Ilias, Ι., Venaki, E., & Koukkou, E. G. (2023) · Biomedicines · doi:10.3390/biomedicines11030670 · Cited by 18
“In cisgender men with both hypogonadism and either prediabetes or diabetes mellitus, the long-term administration of testosterone may improve glycemic control and other components of metabolic syndrome [49,50].”
Safety of testosterone therapy in men with prostate cancer
Morgentaler, A., & Caliber, M. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1666103 · Cited by 15
Self-citationSevere Cardiac and Metabolic Pathology Induced by Steroid Abuse in a Young Individual
Tirla, A. G., Vesa, C. M., & Cavalu, S. D. (2021) · Diagnostics · doi:10.3390/diagnostics11081313 · Cited by 15
Beyond apples and pears: sex-specific genetics of body fat percentage
Roshandel, D., Lu, T., Paterson, A. D., & Dash, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1274791 · Cited by 16
Wang, L., Chen, G., Hou, J., Wei, D., Liu, P., Nie, L., Fan, K., Wang, J., Xu, Q., Song, Y., et al. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112845 · Cited by 13
Abildgaard, J., Petersen, J. H., Bang, A. K., Aksglæde, L., Christiansen, P., Juul, A., & Jørgensen, N. (2021) · Andrology · doi:10.1111/andr.13124 · Cited by 13
Sinha, D. K., Balasubramanian, A., Tatem, A. J., Mirabal, J. L. R., Yu, J., Kovac, J. R., Pastuszak, A. W., & Lipshultz, L. I. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2019.11.30 · Cited by 13
Xie, T., Song, X., Wang, C., Yu, Y., Wang, J., Chen, Z., & Zhao, S. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.034 · Cited by 12
Novaes, M. T., de Carvalho, O. L. F., Ferreira, P. H. G., Tiraboschi, T. L. N., Silva, C. S., Contreras, J. C. Z., Gomes, C. M., Miranda, E., Júnior, O. A. D. C., & de Bessa, J. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100538 · Cited by 16
Kurniawan, A. L., Hsu, C., Chao, J. C.-J., Paramastri, R., Lee, H.-A., Lai, P.-C., Hsieh, N., & Wu, S. V. (2021) · Nutrients · doi:10.3390/nu13010259 · Cited by 13
Wh, K., Sithik, M. N. B. M., Khoo, J. K., Ooi, Y., Lim, Q., & Lim, L. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13903 · Cited by 12
Sex-Related Effects of Gut Microbiota in Metabolic Syndrome-Related Diabetic Retinopathy
García‐Llorca, A., & Kararigas, G. (2023) · Microorganisms · doi:10.3390/microorganisms11020447 · Cited by 11
Testosterone and Glucose Homeostasis in Adult Males: Current Insights and Future Prospects
Milionis, C., Koukkou, E. G., Venaki, E., & Ilias, Ι. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436184.81 · Cited by 12
Testosterone Therapy for Prevention and Treatment of Obesity in Men
Caliber, M., & Saad, F. (2020) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0010 · Cited by 11
“54,88,89,92,93 Because obesity is a gateway to ill health, 207 especially FIG.”
Self-citationJENKINS, C., Rittel, A. G., Sturdivant, R. X., Wan, J., CLERC, P. G., Manning, E., Jenkins, L. M., Wardian, J., & Graybill, S. D. (2021) · Andrology · doi:10.1111/andr.12990 · Cited by 15
Novel methods for the treatment of low testosterone
Fink, J. E., & Horie, S. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2197059 · Cited by 9
“Testosterone replacement therapy (TRT) has been shown to efficiently prevent and improve several of these conditions [3].”
BackgroundChen, B.-T., Tsai, P.-J., & Jiann, B.-P. (2024) · Sexual Medicine · doi:10.1093/sexmed/qfae089 · Cited by 7
Wu, X., Wei, D., Liu, X., Yuchi, Y., Liao, W., Wang, C., Huo, W., & Mao, Z. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.170621 · Cited by 8
Mice lacking the proton channel Hv1 exhibit sex-specific differences in glucose homeostasis
Pang, H., Li, J., Wang, Y., Su, L., Gao, Y., & Li, S. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101212 · Cited by 9
“Low plasma testosterone concentrations, in men with hypogonadism, are associated with an increased risk of type 2 diabetes and vascular disease, and supplementation of testosterone significantly improves glycolipid homeostasis (11).”
BackgroundThe mediation role of SOCS3 methylation in the effect of serum testosterone on type 2 diabetes
Wang, L., Liu, X., Wei, D., Kang, N., Nie, L., Liu, P., Fan, K., Zhang, L., Hou, J., Li, X., et al. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13167 · Cited by 8
Hu, Y., Cai, T.-T., Yan, R., Liu, B., Ding, B., & Ma, J. (2024) · International Journal of Endocrinology · doi:10.1155/2024/8797972 · Cited by 8
Liang, X.-M., Lai, K., Li, X.-H., Li, Y., Xing, Z.-M., & Gui, S.-Q. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02518-5 · Cited by 7
“The exposure variable was the levels of TyG, calculated: Ln [ TG ( mg/dL ) × FPG ( mg/dL ) / 2] [23, 24].”
Undžytė, G., Patašius, A., Linkevičiūtė-Ulinskienė, D., Zabulienė, L., Stukas, R., Dulskas, A., & Smailytė, G. (2020) · The Aging Male · doi:10.1080/13685538.2020.1755249 · Cited by 7
“Testosterone replacement therapy (TRT) is beneficial for stoping prediabetes progression to diabetes [33].”
BackgroundAn Individualized Approach to Managing Testosterone Therapy in the Primary Care Setting
Dobs, A. S., & Campbell, K. J. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s364189 · Cited by 8
“Preliminary evidence also suggests that long-term testosterone therapy may slow prediabetes progression to diabetes in men with hypogonadism and improve glycemic and lipid control.(59,60) It may also enhance the beneficial effects of supervised changes in diet and exercise on glycemic control and insulin sensitivity i…”
BackgroundAntonič, K. G., & Zitzmann, M. (2023) · The Aging Male · doi:10.1080/13685538.2023.2296460 · Cited by 8
“In this study, TTh led to substantial improvements in glycemic parameters, with HbA1c decreasing by 0.39 ± 0.03% in the T-group, in contrast to an increase of 0.63 ± 0.1% in the untreated group [44].”
InfluentialAdvances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Arif, A. I., Rmaidh, A. Y., Qaddoori, H. T., & Mohammad, S. Q. (2025) · Regulatory Mechanisms in Biosystems · doi:10.15421/0225070 · Cited by 6
Mohammed, M. E. A., Alshahrani, S., Zaman, G. S., Alelyani, M., Hadadi, I., & Musa, M. J. (2020) · The Aging Male · doi:10.1080/13685538.2020.1773424 · Cited by 7
Hu, Y., Yuan, L., Bao, Y.-J., Wang, Y., Cai, T., Ma, J., & Ding, B. (2023) · Journal of Diabetes Research · doi:10.1155/2023/2082940 · Cited by 8
“testosterone therapy prevented prediabetes progression to T2DM in men with hypogonadism [10].”
BackgroundSex Differences in Glucose Homeostasis
Arioglu‐Inan, E., & Kayki‐Mutlu, G. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_664 · Cited by 8
Testosterone Replacement Therapy and the Risk of Hypoglycemia
Yamaguchi, A. V., Costanzo, P., Peuchot, V. A., & Knoblovits, P. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/9616125 · Cited by 7
Testosterone deficiency in men infected with COVID ‐19
Hackett, G. I., & Kirby, M. G. (2020) · Trends in Urology & Men s Health · doi:10.1002/tre.773 · Cited by 8
The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems
Antonič, K. G., & Zitzmann, M. (2025) · The Aging Male · doi:10.1080/13685538.2025.2601423 · Cited by 7
“There is considerable evidence from large randomized clinical trials that testosterone treatment improves glycemic control, individual parameters of metabolic syndrome, and sexual symptoms in hypogonadal men with metabolic syndrome and/or T2D [100,101].”
InfluentialMetabolic Messengers: testosterone
Mauvais‐Jarvis, F., & Bhasin, S. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01431-6 · Cited by 7
“Similarly, a registry study using injectable testosterone showed improved glycaemic control, triglyceride levels and LDL-C levels in testosterone-treated hypogonadal men, whereas untreated men exhibited metabolic decline 110 .”
Wu, F. C. W. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101626 · Cited by 6
Yin, L., Tang, H., Qu, J., Jia, Y., Zhang, Q., & Wang, X. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00104.2023 · Cited by 5
Type 2 diabetes mellitus is more commonly well controlled in younger men compared to older men
Koçak, M. Z., Aktaş, G., Duman, T. T., Tel, B. M. A., Bilgin, S., Kurtkulağı, Ö., & Şavlı, H. (2019) · The Aging Male · doi:10.1080/13685538.2019.1621833 · Cited by 6
COVID-19, Type 2 Diabetes, and Hypogonadism: Lessons for Acute Management and Long-Term Prevention
Hackett, G. I., & Kirby, M. G. (2020) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0004 · Cited by 5
“39 Venous thrombotic embolism and testosterone Administration of exogenous testosterone can raise hematocrit values and potentially blood viscosity, along with platelet and thromboxane A2 concentrations, thereby enhancing the risk of venous thromboembolism.”
Congenital Hypogonadotropic Hypogonadism with Early-Onset Coronary Artery Disease
Takashima, A., Yagi, S., Yamaguchi, K., Kurahashi, K., Kojima, Y., Zheng, R., Ise, T., Kusunose, K., Yoshida, S., Yamada, H., et al. (2021) · The Journal of Medical Investigation · doi:10.2152/jmi.68.189 · Cited by 4
“Interestingly, testosterone replacement therapy prevented the progression of prediabetes to type 2 diabetes and improved glycemic control (7).”
BackgroundResultTomar, G., Singh, M., Sharma, I., Nautiyal, A., Aggarwal, S., Chandra, S., Chitme, H. R., Medeiros, C. R., Lima, M. D. A., de Lima, L. R., et al. (2024) · Clinical Traditional Medicine and Pharmacology · doi:10.1016/j.ctmp.2024.200167 · Cited by 5
Antonič, K. G., Antonič, B., & Pfeifer, M. (2020) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0008 · Cited by 4
Chiba, I., Lee, S., Bae, S., Makino, K., Shinkai, Y., & Shimada, H. (2021) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14131 · Cited by 5
Yu, X., Wei, Z., Liu, Y., Zhang, X., & Wang, Q. (2021) · Sexual Medicine · doi:10.1016/j.esxm.2021.100403 · Cited by 4
Demidova, T. Y., Скуридина, Д. В., & Kasimova, A. M. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-10-34-39 · Cited by 4
MiR-143-3p/FNDC5 axis: a novel regulator of insulin sensitivity
Li, B., Dong, Y., Hu, S., & Liu, T. (2023) · Endocrine · doi:10.1007/s12020-023-03522-4 · Cited by 4
Metadata
- Authors
- Yassin, A., Haider, A., Haider, K. S., Caliber, M., Doros, G., Saad, F., & Garvey, W. T.
- Affiliations
- Dresden International University (DE)
- Private Urology Practice, Bremerhaven, Germany
- American Medical Writers Association (US)
- Boston University (US)
- Gulf Medical University (AE)
- University of Alabama at Birmingham (US)
- Corresponding author
- Saad, Farid
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-03-12
- Volume
- 42
- Issue
- 6
- Pages
- 1104-1111
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2922405541
- Cited by
- 164
- References
- 45
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 20 · 2023: 26 · 2022: 31 · 2021: 26 · 2020: 26 · 2019: 11
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer AG
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- testosterone replacement therapy, hypogonadism, prediabetes, type 2 diabetes prevention, testosterone undecanoate, glycemic control, HbA1c, lipid profile, aging male symptoms, myocardial infarction, mortality, men
- MeSH terms
- Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hypogonadism, Male, Middle Aged, Prediabetic State, Registries, Testosterone, Triglycerides, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.